21.01.2021 - 21.01.2021 Optimizing Patient Outcomes in Difficult-to-treat Migraine: What Do the Data Tell Us?
Chronic migraine results in a higher impact on the socioeconomic functioning and quality of life of individuals than does episodic migraine.1 Prevention of migraine chronification is essential, and requires adequate treatment of individual migraine attacks, initiation of preventive medication early and analgesic overuse avoidance.1 However, in one study with 8,233 individuals with episodic migraine, more than 50% of participants reported inadequate pain relief response to acute treatment after 2 hours and 24 hours post-dose.2 The identified risk factors contributing to inadequate sustained pain relief include headache features (i.e. monthly headache day frequency, migraine symptom severity composite score, cutaneous allodynia), depression and medication overuse.2
The European Headache Federation (EHF) recommends the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway in patients with episodic or chronic migraine who have failed two or more prior classes of preventive treatments, or who cannot use other preventive treatment due to comorbidities, side effects or poor compliance.3 In this webinar, Professor Hans-Christoph Diener from the University of Duisburg-Essen, Germany presents the clinical data supporting the use of anti-CGRP monoclonal antibodies in patients with migraine with inadequate treatment response and in patients with medication overuse.
If you missed the live broadcast, follow the link and you can watch Prof. Diener’s webinar on-demand.
May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 2016;12:455-64.
Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2016;56:1635-48.
Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 2019;20:6.